This is the second issue of a recurring series to track the market potential of select products that are likely to impact the market in the coming years.

The report includes both recent and near-term approvals, combining insight from IPD’s expert forecasters with manufacturer earnings reports, presentations, statements, and press releases as well as clinical and regulatory developments.


Market Performance Outlook
Recent and Near-Term Drug Approvals to Watch 
November 2021

Market Performance Outlook Full 2.png

This is the first issue of a bi-annual pipeline report IPD will release in 2022.

In this report, IPD Analytics provides detailed summaries of key drugs nearing potential FDA approval in the coming months.

Our team of pharmacists, PhD scientists, and intellectual property attorneys continuously monitor and update our comprehensive pipeline intelligence database.

This report is used as a companion to our online Clinical Development Tracker, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. In tandem, these reports deliver insight into trending classes that will affect the competitive landscape and your drug spend.


Drug Pipeline Report & Podcast Sample 1H 2022
February 2022

Pipeline Report Sample.png

The FDA’s Priority Review Voucher (PRV) program was designed to incentivize the creation of medications for unmet needs and underserved disease areas.

With PRVs averaging a sales price of over $100 million and a record high sales price of $350 million, this program offers a substantial incentive for the development of medications for three underserved categories: tropical diseases, rare pediatric diseases, and medical countermeasures. The redemption of a PRV may result in benefits to drug manufacturers that include generating revenue 4 months sooner on a drug and/or earning 4 months of additional revenue prior to generic entry, potentially beating a competitor to the market, and getting a drug approved and on payer formularies by the beginning of the year.

In this paper, we evaluate the benefits of using a PRV through three case studies, assess potential return-on-investment (ROI) calculations, provide a summary of PRVs sold to date, and assess how PRVs may be utilized in the future.


Priority Review Voucher.png

The FDA's Priority Review Voucher Program: Potential Benefits and Risks for Manufacturers and Outlook for Future Use
February 2022